Renaissance Technologies (RenTech)'s RNA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 14,971 shares of Atrium Therapeutics, Inc. (RNA) worth $201,360, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in RNA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 377,400 shares. Largest reduction occurred in Q2 2023, reducing 309,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Atrium Therapeutics (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atrium Therapeutics (RNA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +14,971 | New Buy | 14,971 | $13.45 |
| Q1 2026 | -45,100 | Sold Out | 0 | $0.00 |
| Q4 2025 | +45,100 | New Buy | 45,100 | $72.13 |
| Q1 2025 | -211,200 | Sold Out | 0 | $0.00 |
| Q4 2024 | +69,300 | Add 48.84% | 211,200 | $29.08 |
| Q3 2024 | -235,500 | Reduce 62.40% | 141,900 | $45.93 |
| Q2 2024 | +377,400 | New Buy | 377,400 | $40.85 |
| Q1 2024 | -226,700 | Sold Out | 0 | $0.00 |
| Q4 2023 | +115,900 | Add 104.60% | 226,700 | $9.05 |
| Q3 2023 | +44,900 | Add 68.13% | 110,800 | $6.38 |
| Q2 2023 | -309,200 | Reduce 82.43% | 65,900 | $0.01 |
| Q1 2023 | +208,500 | Add 125.15% | 375,100 | $0.02 |
| Q4 2022 | +42,600 | Add 34.35% | 166,600 | $0.02 |
| Q3 2022 | +15,700 | Add 14.50% | 124,000 | $16.33 |
| Q2 2022 | +69,900 | Add 182.03% | 108,300 | $14.53 |
| Q1 2022 | +26,800 | Add 231.03% | 38,400 | $18.46 |
| Q4 2021 | +11,600 | New Buy | 11,600 | $23.79 |
Renaissance Technologies (RenTech)'s Atrium Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Atrium Therapeutics, Inc. (RNA) in Q4 2021, acquiring 11,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Atrium Therapeutics, Inc. (RNA) for 17 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Atrium Therapeutics, Inc. (RNA) was in Q2 2024, adding 377,400 shares worth $15.42 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 14,971 shares of Atrium Therapeutics, Inc. (RNA), valued at approximately $201,360.
As of the Q2 2026 filing, Atrium Therapeutics, Inc. (RNA) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Atrium Therapeutics, Inc. (RNA) was 377,400 shares, as reported at the end of Q2 2024.